A New Biomarker for early Prostate Cancer detection
A study by Prof. Karin showing that autoantibodies are produced against several key mediators of the destructive process in inflammatory autoimmunity and cancer, has been the bases for his development of these autoantibodies as both diagnostic biomarkers and predictive biomarkers for assessing clinical response to therapy. Such a biomarker, for prostate cancer, is now available for licensing.
Professor Nathan Karin, a member of the Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel, was the first researcher to discover natural protective (or beneficial) antibodies (NPA) against pro-inflammatory chemokines and cytokines, and establish their role in the regulation of inflammatory autoimmune diseases (Wildbaum et al., 2003). Based on this finding, he has established a target discovery platform that could be used to discover specific antibodies expressed in different inflammatory and cancerous diseases.
Specifically, Prof. Karin recently reported that autoantibodies are produced against several key mediators of the destructive process in inflammatory autoimmunity and cancer. Accordingly, he has proposed that these autoantibodies could be used as (a) diagnostic biomarkers for early diagnosis of such diseases, and (b) predictive biomarkers for assessing the clinical response to therapy for diseases that include type I diabetes mellitus (Shehadeh et al., 2009), prostate cancer (Izhak et al., 2010), inflammatory bowel disease, and multiple sclerosis.
|
Disease |
Target |
Commercialization Status |
Link to additional information |
|
Prostate cancer |
CCL2 |
Available for Licensing |
Related Links